Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine deriva

来源 :中国药理学报(英文版) | 被引量 : 0次 | 上传用户:hwniuniu
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and an ongoing severe pandemic.Curative drugs specific for COVID-19 are currently lacking.Chloroquine phosphate and its derivative hydroxychloroquine,which have been used in the treatment and prevention of malaria and autoimmune diseases for decades,were found to inhibit SARS-CoV-2 infection with high potency in vitro and have shown clinical and virologic benefits in COVID-19 patients.Therefore,chloroquine phosphate was first used in the treatment of COVID-19 in China.Later,under a limited emergencyuse authorization from the FDA,hydroxychloroquine in combination with azithromycin was used to treat COVID-19 patients in the USA,although the mechanisms of the anti-COVID-19 effects remain unclear.Preliminary outcomes from clinical trials in several countries have generated controversial results.The desperation to control the pandemic overrode the concerns regarding the serious adverse effects of chloroquine derivatives and combination drugs,including lethal arrhythmias and cardiomyopathy.The risks of these treatments have become more complex as a result of findings that COVID-19 is actually a multisystem disease.While respiratory symptoms are the major clinical manifestations,cardiovascular abnormalities,including arrhythmias,myocarditis,heart failure,and ischemic stroke,have been reported in a significant number of COVID-19 patients.Patients with preexisting cardiovascular conditions (hypertension,arrhythmias,etc.) are at increased risk of severe COVlD-19 and death.From pharmacological and cardiovascular perspectives,therefore,the treatment of COVID-19 with chloroquine and its derivatives should be systematically evaluated,and patients should be routinely monitored for cardiovascular conditions to prevent lethal adverse events.
其他文献
会议
目的:建立双标多测(TRSDMC)法同时测定补骨脂中补骨脂苷、异补骨脂苷、补骨脂素、异补骨脂素的含量,在节约对照品同时,更好地控制该品种质量.方法:采用HPLC法测定,使用C18柱,
目的:采用色谱-质谱联用技术鉴定阿司匹林的有关物质.方法:采用Inertsil-C8色谱柱(250mm×4.6 mm,5μm),以乙腈-水-甲酸为流动相,梯度洗脱,对阿司匹林有关物质进行分离,采用
会议
目的:建立益血生胶囊中的阿胶、龟甲胶和鹿角胶的专属性检测方法.方法:采用胰蛋白酶对益血生胶囊中胶类成分进行酶解,利用超高效液相色谱-三重四极杆质谱(UPLC-QQQ MS)对阿胶
罗易,广东省人民政府督学、广东省中学特级教师、广东省首届名师,任教于广东实验中学,任广州市中学语文教学研究会副会长 Luo Yi, Governor of Guangdong Provincial People
会议
会议
阐述了后张长直力筋张拉管理的有效方法,在实测参数的基础上提出了计算长直力筋理论伸长值的计算公式,给出了尹山大桥系杆拱加劲梁预应力束的双控张拉资料和数据,并对预应力工程
目的:对甲磺酸阿帕替尼有关物质进行结构鉴定.方法:采用ACQUITY UHPLC30 HSS C18色谱柱(50 mm×2.1 mm,1.7 μm),以0.1%甲酸水-乙腈为流动相梯度洗脱,对阿帕替尼有关物质进行